» Articles » PMID: 19303015

Angiotensin II Activates I KappaB Kinase Phosphorylation of RelA at Ser 536 to Promote Myofibroblast Survival and Liver Fibrosis

Overview
Specialty Gastroenterology
Date 2009 Mar 24
PMID 19303015
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: The transcription factor nuclear factor-kappaB (NF)-kappaB promotes survival of hepatic myofibroblasts and fibrogenesis through poorly defined mechanisms. We investigated the activities of angiotensin II and I kappaB kinase (IKK) in regulation of NF-kappaB activity and the role of these proteins in liver fibrosis in rodents and humans.

Methods: Phosphorylation of the NF-kappaB subunit RelA at serine 536 (P-Ser(536)-RelA) was detected by immunoblot and immunohistochemical analyses. P-Ser(536)-RelA function was assessed using vectors that expressed mutant forms of RelA, cell-permeable blocking peptides, and assays for RelA nuclear transport and apoptosis. Levels of P-Ser(536)-RelA were compared with degree of fibrosis in liver sections from chronically injured rats and patients with hepatitis C virus-mediated fibrosis who had been treated with the AT1 antagonist losartan.

Results: Constitutive P-Ser(536)-RelA is a feature of human hepatic myofibroblasts, both in vitro and in situ in diseased livers. Autocrine angiotensin II stimulated IKK-mediated phosphorylation of RelA at Ser(536), which was required for nuclear transport and transcriptional activity of NF-kappaB. Inhibition of angiotensin II, the angiotensin II receptor type 1 (AT1), or IKK blocked Ser(536) phosphorylation and stimulated myofibroblast apoptosis. Treatment of fibrotic rodent liver with the angiotensin converting enzyme (ACE) inhibitor captopril or the IKK inhibitor sulphasalazine resulted in loss of P-Ser(536)-RelA-positive myofibroblasts and fibrosis regression. In human liver samples, increased numbers of P-Ser(536)-RelA-positive cells were associated with fibrosis that regressed following exposure to losartan.

Conclusions: An autocrine pathway that includes angiotensin II, IKK, and P-Ser(536)-RelA regulates myofibroblast survival and can be targeted to stimulate therapeutic regression of liver fibrosis.

Citing Articles

PBX1 attenuates inflammation and apoptosis of trophoblast cells induced by LPS through downregulating the transcription of TMUB1: PBX1 ameliorates RSA development.

Zhang X, Wang S, Liang L, Hu F, Zhang X, Cui X J Mol Histol. 2025; 56(2):91.

PMID: 39961876 DOI: 10.1007/s10735-025-10364-z.


Impaired RelA signaling and lipid metabolism dysregulation in hepatocytes: driving forces in the progression of metabolic dysfunction-associated steatotic liver disease.

He Y, Jiang J, Ou L, Chen Y, Abudukeremu A, Chen G Cell Death Discov. 2025; 11(1):49.

PMID: 39910053 PMC: 11799324. DOI: 10.1038/s41420-025-02312-3.


polysaccharides alleviate metabolic dysfunction-associated steatotic liver disease through enhancing hepatocyte RelA/ HNF1α signaling.

He Y, Ou L, Jiang J, Chen Y, Abudukeremu A, Xue Y World J Gastroenterol. 2025; 31(4):93179.

PMID: 39877717 PMC: 11718647. DOI: 10.3748/wjg.v31.i4.93179.


The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment.

Michalopoulou E, Thymis J, Lampsas S, Pavlidis G, Katogiannis K, Vlachomitros D J Clin Med. 2025; 14(2).

PMID: 39860434 PMC: 11765821. DOI: 10.3390/jcm14020428.


Sex Hormone: A Potential Target at Treating Female Metabolic Dysfunction-Associated Steatotic Liver Disease?.

Duan H, Gong M, Yuan G, Wang Z J Clin Exp Hepatol. 2024; 15(2):102459.

PMID: 39722783 PMC: 11667709. DOI: 10.1016/j.jceh.2024.102459.